EP3478323B1 - Cleavable polymer drug conjugates - Google Patents

Cleavable polymer drug conjugates Download PDF

Info

Publication number
EP3478323B1
EP3478323B1 EP17733906.6A EP17733906A EP3478323B1 EP 3478323 B1 EP3478323 B1 EP 3478323B1 EP 17733906 A EP17733906 A EP 17733906A EP 3478323 B1 EP3478323 B1 EP 3478323B1
Authority
EP
European Patent Office
Prior art keywords
formula
polymer
drug conjugate
natural number
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP17733906.6A
Other languages
German (de)
French (fr)
Other versions
EP3478323A1 (en
Inventor
Rana SANYAL
Amitav SANYAL
Mehmet Arslan
Burcu SUMER BOLU
Ozgul GOK
Merve KARACIVI
Sadik KAGA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret AS
Original Assignee
Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret AS filed Critical Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret AS
Priority to HRP20231642TT priority Critical patent/HRP20231642T1/en
Priority to EP23178285.5A priority patent/EP4260874A1/en
Publication of EP3478323A1 publication Critical patent/EP3478323A1/en
Application granted granted Critical
Publication of EP3478323B1 publication Critical patent/EP3478323B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
    • C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
    • C08F220/285—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing a polyether chain in the alcohol moiety
    • C08F220/286—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing a polyether chain in the alcohol moiety and containing polyethylene oxide in the alcohol moiety, e.g. methoxy polyethylene glycol (meth)acrylate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/52—Amides or imides
    • C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C08F220/60—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing nitrogen in addition to the carbonamido nitrogen
    • C08F220/603—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing nitrogen in addition to the carbonamido nitrogen and containing oxygen in addition to the carbonamido oxygen and nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
    • C08F222/10—Esters
    • C08F222/1006—Esters of polyhydric alcohols or polyhydric phenols
    • C08F222/106—Esters of polycondensation macromers
    • C08F222/1063—Esters of polycondensation macromers of alcohol terminated polyethers

Definitions

  • This invention relates to polymer drug conjugates according to formula I, methods of preparing said polymer-drug conjugates and their use for treatment of diseases such as cancer.
  • Chemotherapy agents used for treatment of cancer are mostly cytotoxic. These agents may accumulate in the tissues of the body in addition to the targeted area, which in turn causes lowered therapeutic benefit and undesired distribution of the drug throughout healthy body tissues. The uncontrolled distribution of these agents throughout the body causes severe side effects to the patient.
  • chemotherapy agents Due to distribution of the chemotherapy agents to the entire body including the healthy tissue, the amount of chemotherapy agent reaching the tumor tissue is very low despite the high overall toxicity caused by the given dose. This situation leads to low therapeutic benefit for the patient. Moreover, chemotherapy agents have low solubility which makes them difficult to formulate and administer to the patient.
  • EPR enhanced permeability and retention effect
  • US 6310039 disclose conjugates of transferrin, albumin and polyethylene glycol and cytostatic compounds such as doxorubicin, daunorubicin, epirubicin etc.
  • the drug molecules are attached to the end groups of a polyethylene glycol polymer.
  • One drawback of these systems is that they have limited functional groups for drug conjugation as a result they have a low drug percentage on the final drug polymer conjugate.
  • aggregation is another phenomenon that is hard to deal with for this type of polymer drug conjugates.
  • WO 1998/056424 discloses a polymer drug conjugate wherein dextrin forms the backbone of the polymer and the drug molecules are either directly or indirectly bound to the polymer backbone.
  • WO 2007/028347 discloses a method for preparing a polymeric conjugate of the doxorubicine, which is an anti-cancer drug molecule.
  • the document teaches use of N-(2-hydroxy propyl) methacrylamide (HPMA) monomer for formation of the polymer.
  • US 2003/0215395 discloses a cationic polymer such as poly(L-lycine), polyethylene imine and chitosan conjugated to a drug with a linker.
  • HPMA based polymer drug conjugates where GFLG is used as a cleavable linker and doxorubicin is used as a therapeutic agent.
  • HPMA was preferred because it is hydrophilic, biocompatible and as a result a water soluble polymeric drug carrier is obtained.
  • the above systems employ drug molecules attached to the polymer backbone via a linker aiming cleavage of the linker after the polymer-drug conjugate reaches its target tissue, thus releasing the drug molecule at the target site.
  • the disadvantage of these systems is that the cleavable linker between the drug and the polymer cleaves in the blood stream and releases the drug molecule before it reaches its target tissue.
  • Another object of the present invention is to provide a polymer-drug conjugate which addresses the problem of drug cleavage before the polymer drug conjugate reaches the targeted tissue.
  • a polymer-drug conjugate according to present invention has considerably higher circulation time, provides selective distribution of the active agent to the targeted tissues, has lower volume of distribution, lower clearance, and higher maximum concentration (Cmax) and higher total area under the curve (AUC total) values.
  • Present invention relates to a polymer-drug conjugate as shown in Formula I for delivery of therapeutic agents comprising a (meth)acrylate based polymer backbone characterized in that the polymer comprises at least two types of side chains wherein one of the side chains is a PEG chain such as -COOCH 2 CH 2 (OCH 2 CH 2 ) n OR 3 wherein n is a natural number between 1-200 and R 3 is selected from a group comprising H or -CH 3 and the other side chain is comprising at least one therapeutic agent covalently bonded to a cleavable linker.
  • the invention relates to a polymer-drug conjugate of Formula I, wherein; R 1 and R 2 are independently selected from H or -CH 3 ; R 3 is selected from -H or -CH 3 ; x is a natural number between 1-140; y is a natural number between 1-40; n is a natural number between 1-200 and L is a cleavable linker and D is at least one therapeutic agent, Z is selected from N or O; A is an end group that is optionally a polymerization initiator or a fragment thereof ; B is an end group that is optionally a polymerization initiator or a fragment thereof
  • the inventors have surprisingly found that in addition to overcoming the disadvantages of the prior art drug delivery systems comprising polymer-drug conjugates; the polymer of the present invention has reduced accumulation in the other organs due to the presence of biodegradable PEG side chains. This, in turn, provides a polymer-drug conjugate that has lower toxicity.
  • polymer-drug conjugate refers to a polymeric structure having a therapeutic agent covalently attached to the polymer.
  • polymeric backbone and “polymer backbone” can be used interchangeably and refer to a polymer chain having side chains or pendant groups.
  • a side chain may have an oligo ethylene glycol unit and a pendant group may be bearing one therapeutic agent or any other group that can be utilized to attach a therapeutic and/or diagnostic agent or a targeting group.
  • acrylate refers to derivatives of acrylic acids. These derivatives include the parent acid (CH 2 CHCO 2 H) and esters, thus the term “acrylate based” defines functional groups having any of the abovementioned acrylate derivatives.
  • methacrylate refers to derivatives of methacrylic acids. These derivatives include the parent acid (CH 2 C(CH 3 )CO 2 H) and esters. Thus the term “methacrylate based” defines functional groups having any of the abovementioned methacrylate derivatives.
  • (meth)acrylate refers to the terms “acrylate” and “methacrylate”.
  • the term “(meth)acrylate” can be used interchangeably with “acrylate” and “methacrylate” and comprises all features of these terms as described above.
  • the term “(meth)acrylate” should be construed to mean “methacrylate and/or acrylate”
  • the term “the polymer-drug conjugate of the invention” should be construed to mean “a polymer-drug conjugate according to formula I” or "a polymer-drug conjugate of formula I” or “formula I” and these terms can be used interchangeably.
  • PEG refers to a polyether compound having the structure of H-(O-CH 2 -CH 2 )n-OR 3 , n being a natural number between 1-200 and R 3 selected from H or -CH 3 .
  • PEG is defined as an oligomer or polymer of ethylene oxide.
  • PEG polyethylene glycol
  • PEG polyethylene oxide
  • POE polyoxyethylene
  • the polymer-drug conjugate of the invention comprises PEG side chains.
  • the side chains provide important physicochemical properties to the polymer-drug conjugate of the invention and leads to a polymer-drug conjugate that has better physicochemical properties in comparison to the conjugates that does not have said side chains.
  • L in formula I denotes a cleavable linker.
  • Cyleavable linker refers to a group that spatially separates drug or a targeting group from the carrier molecule.
  • linker refers to the same entity and can be used interchangeably.
  • short peptide should be construed to mean a peptide chain comprising 1-50 aminoacids, preferably 2-40 aminoacids and most preferably 2-30 aminoacids.
  • random copolymer refers to a copolymer wherein the monomers forming the copolymer follow in any order.
  • block copolymer refers to a copolymer wherein all of one type of monomer is grouped together and the all of the other type of monomers are grouped together.
  • the polymer-drug conjugates of the invention can be in the form of block copolymer or random copolymers.
  • the polymer-drug conjugates of the invention are in the form of random copolymer.
  • the linkers are cleavable so that the therapeutic agent can be released, for example, under reducing conditions, oxidizing conditions or by hydrolysis of an ester, amide, hydrazide, or similar linkage that forms the covalent bond between the linker and the therapeutic agent. Additionally, the type of linker may augment the selective cytotoxicity (and thus improve the therapeutic index) aspect by permitting selective release of the therapeutic agent adjacent to or inside the cell.
  • Said cleavable linker can be any hydrocarbon or substituted hydrocarbon based compound which is capable of dissociating under physiological conditions.
  • the linker can be selected from compounds that are cleaved under the acidic conditions of the tumor (such as any C 1 -C 10 substituted hydrocarbon comprising an acetal or an ester functional group) or with the help of the overexpressed enzymes present in the intercellular or intracellular matrix of the tumor cells.
  • the linker can be any sort of entity capable of binding to both the polymer backbone and to the drug, such as, a poly(ethylene glycol), an amino acid, poly(amino acid) (e.g. a peptide or oligopeptide), or polypeptide (e.g. a protein), such that one end of it is capable of forming a covalent bond with the polymer backbone and the other end of it is capable of forming a covalent bond with the therapeutic agent.
  • a poly(ethylene glycol) an amino acid
  • poly(amino acid) e.g. a peptide or oligopeptide
  • polypeptide e.g. a protein
  • the linkers may also include short peptides with specific peptide sequences that are cathepsin B labile, such as Gly-Phe-Leu-Gly (SEQ ID NO: 1) also denoted as GFLG or Val-Cit or Phe-Lys or Val-Ala or Ala-Leu-Ala-Leu (SEQ ID NO: 2)
  • the linker can also be a C 1 -C 10 hydrocarbon or a C 1 -C 10 substituted or hetero substituted hydrocarbon such that it comprises a functional group that dissociates under physiological conditions, such as an acetal, ester, imine, amide, disulfide, carbonate, carbamate, hydrazone.
  • C 1 -C 10 hydrocarbon refers to a hydrocarbon chain having 1 to 10 C atoms in the backbone.
  • C 1 -C 10 substituted hydrocarbon refers to a hydrocarbon chain having 1 to 10 C atoms in the backbone wherein one or more of its hydrogen atoms replaced by atoms of groups of other elements such as alcohol, amine, carboxyl, thiol etc.
  • C 1 -C 10 heterosubstituted hydrocarbon refers to a hydrocarbon chain having 1 to 10 C atoms in the backbone wherein at least one of the C atoms is substituted with an atom other than C such as nitrogen, oxygen, phosphorus, sulfur or a halogen atom.
  • substituents include but not limited to lower alkoxy such as methoxy, ethoxy, butoxy; ethers; acetals; ketals; esters; hetroaryl; heterocyclic; hydroxyl; protected hydroxyl; acyl; acyloxy; amino; amido; imine, disulfide, carbonate, carbamate, hydrozone, hydrazine.
  • the linker (L) is GFLG. In an embodiment of the invention, the linker is Val-Cit. In an embodiment of the invention, the linker is Phe-Lys. In an embodiment of the invention, the linker is Val-Ala. In an embodiment of the invention, the linker is Ala-Leu-Ala-Leu.
  • the linker is a C 1 -C 10 hetero substituted hydrocarbon comprising at least one disulfide functional group. In an embodiment of the invention the linker is a C 1 -C 10 hetero substituted hydrocarbon comprising at least one acetal functional group. In an embodiment of the invention the linker is a C 1 -C 10 hetero substituted hydrocarbon comprising at least one ester functional group. In an embodiment of the invention the linker is a C 1 -C 10 hetero substituted hydrocarbon comprising at least one imine functional group. In an embodiment of the invention the linker is a C 1 -C 10 hetero substituted hydrocarbon comprising at least one amide functional group.
  • the linker is a C 1 -C 10 hetero substituted hydrocarbon comprising at least one carbonate functional group. In an embodiment of the invention the linker is a C 1 -C 10 hetero substituted hydrocarbon comprising at least one carbamate functional group. In an embodiment of the invention the linker is a C 1 -C 10 hetero substituted hydrocarbon comprising at least one hydrazone functional group.
  • the linker may comprise a C 1 -C 10 substituted or hetero substituted hydrocarbon comprising two or more functional groups selected from the group comprising acetal, ester, imine, amide, disulfide, carbonate, carbamate, hydrazone.
  • the linker may be a combination of a C 1 -C 10 substituted hydrocarbon comprising at least one functional group selected from the group comprising acetal, ester, imine, amide, disulfide, carbonate, carbamate, hydrazone and a peptide chain selected from the group comprising GFLG, Val-Cit or Phe-Lys or Val-Ala or Ala-Leu-Ala-Leu.
  • therapeutic agent refers to any compound that is suitable for use in treatment of a disease.
  • therapeutic agent refers to any compound that is suitable for use in treatment of a disease.
  • chemotherapy agent refers to the compounds suitable for use in treatment of a disease and these terms can be used interchangeably.
  • the disease is cancer.
  • a "therapeutic agent” also refers to any agent that is suitable for use in treating of a disease, for example cancer. Any therapeutic agent which can be directly or indirectly attached to the polymer-drug conjugate of the invention can be used.
  • U.S. Patent Nos 6 6,342,221 also describe agents related to anticancer agents and this document is incorporated herein by reference.
  • Anticancer agents can be classified as but are not limited to, chemotherapeutic agents, cytotoxins, antimetabolites, alkylating agents, protein kinase inhibitors, anthracyclines, antibiotics, antimitotic agents (e.g. antitubulin agents), corticosteroids, radiopharmaceuticals, and proteins (e.g. cytokines, enzymes, or interferons).
  • anticancer agents are for example, docetaxel, gemcitabine, imatinib, 5-fluorouracil, 9-aminocamptothecin, amine-modified geldanamycin, doxorubicin, paclitaxel, procarbazine, hydroxyurea, meso e-chlorin, cisplatin and radionuclides (e.g 1-131, Y-90, In-111, and Tc-99m).
  • radionuclides e.g 1-131, Y-90, In-111, and Tc-99m.
  • the therapeutic agent(s) can also be selected from a sub group comprising, but not limited to, nucleoside analogs, antifolates, other metabolites, topoisomerase I inhibitors, anthracyclines, podophyllotoxins, taxanes, vinca alkaloids, alkylating agents, platinum compounds, antihormones, radiopharmaceutics, monoclonal antibodies, tyrosine kinase inhibitors, mammalian target of rapamycin (mTOR) inhibitors, retinoids, immunomodulatory agents, histonedeacetylase inhibitors and other agents.
  • nucleoside analogs nucleoside analogs, antifolates, other metabolites, topoisomerase I inhibitors, anthracyclines, podophyllotoxins, taxanes, vinca alkaloids, alkylating agents, platinum compounds, antihormones, radiopharmaceutics, monoclonal antibodies, tyrosine kinase inhibitors, mamma
  • Nucleoside analogs can be selected from a group comprising, but not limited to, azacitidine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabine, fluorouracil (5-FU), gemcitabine, mercaptopurine, nelarabine, pentostatin, tioguanine, trifluridine, tipiracil.
  • Antifolates can be selected from a group comprising, but not limited to, methotrexate, pemetrexed, pralatrexed, raltitrexed. Other metabolites can be selected from a group comprising, but not limited to, hydroxycarbamide.
  • Topoisomerase I inhibitors can be selected from a group comprising, but not limited to, irinotecan and topotecan.
  • Anthracyclines can be selected from a group comprising, but not limited to, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, valrubicin.
  • Podophyllotoxins can be selected from a group comprising, but not limited to, etoposide and teniposide.
  • Taxanes can be selected from a group comprising, but not limited to, cabazitaxel, docetaxel, paclitaxel.
  • Vinca alkaloids can be selected from a group comprising, but not limited to, vinblastine, vincristine, vindesine, vinflunine, vinorelbine.
  • Alkylating agents can be selected from a group comprising, but not limited to, bendamustine, chlorambucil, dacarbazine, melphalan, streptozotocin, trabectedin.
  • Antihormone compounds can be selected from a group comprising, but not limited to, abiraterone, bicalutamide, cyproterone, degarelix, exemestane, fulvestrant, goserelin, histrelin, leuprolide, mifepristone, triptorelin.
  • Tyrosine kinase inhibitors can be selected from a group comprising, but not limited to, afatinib, axitinib, bosutinib, cobimetinib, crizotinib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, osimertinib, pazopanib, ruxolitinib, sunitinib, vandetanib.
  • Mammalian target of rapamycin (mTOR) inhibitors can be selected from a group comprising, but not limited to everolimus, temsirolimus.
  • Retinoids can be selected from a group comprising, but not limited to, alitretinoin, bexarotene, isotretinoin, tamibarotene, tretinoin.
  • Immunomodulatory agents can be selected from a group comprising, but not limited to, lenalidomide, pomalidomide, thalidomide.
  • Histone deacetylase inhibitors can be selected from a group comprising, but not limited to, belinostat, panobinostat, valproate, vorinostat.
  • agents can be selected from a group comprising, but not limited to, anagrelide, ceritinib, dabrafenib, idelalisib, ibrutinib, palbociclib, vemurafenib, bleomycin, bortezomib, dactinomycin, eribulin, estramustine, ixabepilone, mitomycin, procarbazine, alectinib, fluxymesterone, iobenguane, imiguimod, interferon, ixazomib, lanreotide, lentinan, octreotide, omacetaxine, tegafur, gimerazil, oteracil, uracil, combretastatin, chloroquine.
  • the therapeutic agent(s) is selected from taxanes, antifolates, tyrosine kinase inhibitors, anthracyclines, nucleoside analogs or other agents. Most preferably the therapeutic agent(s) is selected from a group comprising docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, Fluorouracil (5-FU), 5'-Deoxy 5-Fluorocytidine (5'-DFCR), lapatinib and any of the therapeutic agents listed above. As such the therapeutic agents are selected from taxanes, antifolates, tyrosine kinase inhibitors, anthracyclines, nucleoside analogs or other agents. Most preferably the therapeutic agent(s) is selected from a group comprising docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, Fluorouracil (5-FU), 5'-
  • agent(s) refer to at least one or more therapeutic agents.
  • the therapeutic agent is docetaxel. In an embodiment of the invention the therapeutic agent is pemetrexed. In an embodiment of the invention the therapeutic agent is chloroquine. In an embodiment of the invention the therapeutic agent is combretastatin. In an embodiment of the invention the therapeutic agent is gemcitabine. In an embodiment of the invention the therapeutic agent is doxorubicine. In an embodiment of the invention the therapeutic agent is 5-FU. In an embodiment of the invention the therapeutic agent is 5'-Deoxy 5-Fluorocytidine (5'-DFCR). In an embodiment of the invention the therapeutic agent is lapatinib.
  • the therapeutic agent is a combination of two or more therapeutic agents selected from the group comprising docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, 5-FU, 5'-Deoxy 5-Fluorocytidine (5'-DFCR) and lapatinib and any other agents listed above.
  • therapeutic agent(s) that are a combination of two or more therapeutic agents can be selected from the main groups or specific members of the main groups listed above.
  • the therapeutic agent can be present in an amount in between 1% to 40% by weight of the polymer-drug conjugate, preferably in an amount between 2% to 35% by weight of the drug-polymer conjugate and most preferably in an amount between 3% to 30% by weight of the drug-polymer conjugate.
  • the therapeutic agent can be present in an amount in the range of for example; 4% to 25% or 5% to 24% or 6% to 23% or 7% to 22% or 8% to 20% by weight of the drug-polymer conjugate.
  • end group refers to functionalities or constitutional units that are at the extremity of a polymer.
  • the end groups shown as A and B can be identical to or different from one another.
  • a and B can optionally be a polymerization initiator or a fragment thereof. Particularly when an initiator is used in the polymerization reaction, the initiator fragment may stay as an end group to the polymer.
  • the initiator used herein, may be any material suitable for initiating the polymerization reaction known in the art.
  • a and/or B is selected from the group consisting of 4,4'-Azobis(4-cyanovaleric acid), 4,4'-Azobis(4-cyanovaleric acid), 1,1'-Azobis(cyclohexanecarbonitrile), 2,2'-Azobis(2-methylpropionamidine) dihydrochloride, 2,2'-Azobis(2-methylpropionitrile) (also known as AIBN), Ammonium persulfate, hydroxymethanesulfinic acid monosodium salt dihydrate, potassium persulfate, sodium persulfate, tert-Butyl hydroperoxide, tert-Butyl peracetate, Cumenehydroperoxide, 2,5-Di(tert-butylperoxy)-2,5-dimethyl-3-hexyne, Dicumyl peroxide, 2,5-Bis(tert-butylperoxy)-2,5-dimethylhexane, 1,1
  • fragment refers to compounds that form due to breaking of one or more of the covalent bonds forming the initiator molecule.
  • a and B are both fragments of a polymerization initiator however they are structurally different from one another. In other words, A and B are different fragments of the same initiator. In another embodiment A and B are both fragments of a polymerization initiator and they have the same chemical structure.
  • the polymer drug conjugate of invention comprise one or more of the following;
  • the measurement of the amount of drug in the polymer conjugate of the invention is made by using conventional techniques well-known in the art, for example by calculation of the drug ratio from an 1 H-NMR of the polymer-drug conjugate.
  • the polymer-drug of the invention has an average molecular weight in between 20 kDa to 300 kDa, preferably between 30 Da to 270 kDa, most preferably between 40 kDa to 250 kDa.
  • Molecular weight of the polymer-drug conjugate of the invention is determined by using conventional techniques known in the art for example by using gel permeation chromatography (GPC).
  • Another embodiment of the invention is a method (Method I) for preparation of the polymer-drug conjugate of the invention (formula I) which comprises polymerization of PEG (meth)acrylate monomer (Formula II) and at least one type of (meth)acrylate-L-D monomer (Formula IIIa) wherein R 1 and R 2 are independently selected from H or -CH 3 , R 3 is selected from -H or -CH 3 , L is a cleavable linker, D is at least one therapeutic agent and n is a natural number between 1-200
  • a method (Method II) for preparation of the polymer-drug conjugate of the invention comprises (i) polymerization of PEG (meth)acrylate monomer (Formula II) and (meth)acrylate-L monomer (Formula IIIb) wherein R 1 and R 2 are independently selected from H or -CH 3 , R3 is selected from -H or -CH 3 , L is a cleavable linker and n is a natural number between 1-200 to give a copolymer as shown in formula IV wherein x is a natural number between 1-100 and y is a natural number between 1-100, Z is selected from O or NH, A is an end group that is optionally a polymerization initiator or a fragment thereof , B is an end group that is optionally a polymerization initiator or a fragment thereof , and then (ii) reacting formula IV with at least one type of therapeutic agent (D) to give polymer conjugate shown in formula I
  • a method (method III) for preparation of the polymer-drug conjugate of the invention comprises (i) polymerization of PEG (meth)acrylate monomer shown with Formula II and (meth)acrylate monomer shown with Formula IIIc wherein n is a natural number between 1-200 and, R 1 and R 2 are independently selected from H or -CH 3 , R 3 is selected from -H or -CH 3 , R 4 is selected from carbonyl activating groups such as perfluorophenoxy, maleimide, carbonate, thiazolidone-2-thione, N-oxybenzotriazole, imidazolyl, o/p-nitrophenol, pentachloro-phenol, N-hydroxysuccinimide, acetates, formates, 2,3,5-trichlorophenol, 8-hydroxyquinoline, -OCH 3 , -OCH 2 CH 3 , Cl, F, Br, H, -SH, -NH 2 , -NHR 5 or
  • carbonyl activating group refers to leaving group of a carboxyl derivative that is easily replaced by an incoming nucleophile.
  • a method (method IV) for preparation of the polymer-drug conjugate of the invention comprises (i) polymerization of PEG (meth)acrylate monomer (Formula II) and (meth)acrylate monomer (Formula IIIc); wherein n is a natural number between 1-200 and, R 1 and R 2 are independently selected from H or -CH 3 , R 3 is selected from -H or -CH 3 , R 4 is selected from carbonyl activating groups such as perfluorophenoxy, maleimide, carbonate, thiazolidone-2-thione, N-oxybenzotriazole, imidazolyl, o/p-nitrophenoxy, pentachloro-phenoxy, N-hydroxysuccinimide, acetates, formates, 2,3,5-trichlorophenol, 8-hydroxyquinoline, -OH, -OCH 3 , -OCH 2 CH 3 , Cl, F, Br, H, -SH, -NH
  • the terms "at least one therapeutic agent” and “at least one type of therapeutic agent” are used interchangeably and refer to use of structurally different therapeutic agents or in other words refer to attachment of one or more such as two, three, four etc. different therapeutic agents onto the polymers according to present invention, as such the terms does not refer to quantitative amount used in the polymer structure.
  • the term “at least one type of (meth)acrylate-L-D monomer” refers to monomer structures having one or more such as two, three or four etc. different therapeutic agents as molecule D.
  • the invention relates to polymer-drug conjugate of formula I prepared by any one of the methods I, II, III or IV.
  • Polymer-drug conjugate of formula I prepared by methods I, II, III or IV has a random copolymer structure which has advantageous technical effects.
  • PEG (meth)acrylate (Formula II) is preferably selected from a group comprising; polyethylene glycol methyl ether methacrylate, polyethylene glycol methacrylate, polyethylene glycol methyl ether acrylate, and poly ethylene glycol acrylate.
  • polyethylene glycol methyl ether methacrylate, wherein R 1 and R 3 are both-CH 3 is used.
  • PEG (meth)acrylate has an average molecular weight in between 200-2000 g/mol, preferably between 250-1500 g/mol, most preferably 300-1100 g/mol is used.
  • the cleavable linker according to present invention can be obtained from commercial sources or may be prepared according to known methods provided in literature.
  • methods for preparing the polymer drug conjugate of formula I comprise at least one polymerization step, wherein monomers formula II and monomers of formula IIIa or IIIb or IIIc are polymerized.
  • these polymerization steps further comprise an initiator and/or a solvent.
  • the polymer-drug conjugate of the invention can be prepared by any of the known polymerization methods. Any suitable initiators and/or catalysts known in the art can be used for the preparation of the polymer-drug conjugate of the present invention. Where a polymerization initiator is used, the initiator or a fragment thereof may be present in the resulting polymer-drug conjugate.
  • the polymer backbone of the polymer-drug conjugate of the invention can be obtained by for example bulk polymerization, solution polymerization and/or suspension polymerization techniques known in the art.
  • the polymerization technique used for the preparation of the polymer-drug conjugate of the present invention may propagate through free-radical polymerization or controlled/living free radical polymerization.
  • controlled/living free radical polymerization refers to atom transfer radical polymerization (ATRP), Reversible addition fragmentation chain transfer (RAFT) polymerization, iodine transfer polymerization (ITP), selenium centered radical mediated polymerization, telluride mediated polymerization (TERP), nitroxide mediated polymerization (NMP).
  • RAFT polymerization is used to prepare the polymer-drug conjugates of the invention.
  • a polymerization initiator as used herein refers to a chemical compound that reacts with a monomer to form an intermediate compound capable of linking successively with a large number of other monomers into a polymeric compound.
  • a polymerization initiator selected from the group disclosed in the above paragraphs of this document.
  • methods I, II, III and/or IV used to prepare the polymer-conjugate of formula I comprises use of AIBN as initiator in the polymerization reactions.
  • the polymer-drug conjugate of the invention can further comprise targeting groups.
  • targeting group refers to tumor specific ligands that bind specifically to the cell, preferably the tumor cell that has a complimentary receptor.
  • targeting group means a molecule which serves to deliver the polymer-drug conjugate of the invention to a specific site for the desired activity, i.e. it provides localization of the compound.
  • the localization is mediated by specific recognition of molecular determinants, molecular size of the targeting agent or conjugate, ionic interactions, hydrophobic interactions, and the like.
  • Other mechanisms of targeting an agent to a particular tissue or region are known to those of skill in the art.
  • Targeting ligands include, for example, molecules that bind to molecules on a targeted cell surface.
  • targeting ligands include antibodies, antibody fragments, small organic molecules, peptides, peptoids, proteins, polypeptides, oligosaccharides, transferrin, HS- glycoprotein, coagulation factors, serum proteins, beta-glycoprotein, G-CSF, GM-CSF, M-CSF, EPO, and the like.
  • the targeting system includes covalently attaching a targeting ligand such as RGDfK, EPPT1 peptide, bisphosphonic acid or folate to the carrier molecule or linker.
  • the present invention is characterized by polymer-drug conjugates with or without a targeting ligand.
  • the targeting ligand can be RGDfK, EPPT1, bisphosphonic acid or folate.
  • Another embodiment of the present invention provides a method for delivering a therapeutic agent, comprising administering to a subject an effective amount of polymer-drug conjugate shown with formula I.
  • Another embodiment of the invention is the polymer-drug conjugate of the invention for use in treatment of a variety of disorders that require the delivery of anticancer or similar agents.
  • the invention is related to a polymer-drug conjugate shown with formula I for use as a medicament for treatment of cancer.
  • treat means to inhibit, reduce, modulate, ameliorate, or block at least one symptom that characterizes a pathologic condition, in a subject threatened by, or afflicted with, the condition.
  • a non-limiting list of different types of cancers is as follows: carcinomas, carcinomas of solid tissues, squamous cell carcinomas, adenocarcinomas, sarcomas, gliomas, high grade gliomas, blastomas, neuroblastomas, plasmacytomas, histiocytomas, melanomas, adenomas, hypoxic tumours, myelomas, metastatic cancers, or cancers in general.
  • cancers that the disclosed compositions can be used to treat include B cell lymphoma, T cell lymphoma, mycosis fungoides, Hodgkin's Disease, bladder cancer, brain cancer, nervous system cancer, head and neck cancer, squamous cell carcinoma of head and neck, kidney cancer, lung cancers such as small cell lung cancer and non-small cell lung cancer, neuroblastoma/glioblastoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, liver cancer, melanoma, squamous cell carcinomas of the mouth, throat, larynx, colon cancer, cervical cancer, cervical carcinoma, breast cancer, and epithelial cancer, renal cancer, genitourinary cancer, pulmonary cancer, esophageal carcinoma, head and neck carcinoma, large bowel cancer, hematopoietic cancers; testicular cancer; colon and rectal cancers, prostatic cancer, or pancreatic cancer.
  • lung cancers such as small cell lung cancer and non-small cell lung cancer, neuroblastom
  • Polymer-drug conjugates of the invention may also be used for the treatment of precancer conditions such as cervical and anal dysplasias, other dysplasias, severe dysplasias, hyperplasias, atypical hyperplasias, and neoplasias.
  • precancer conditions such as cervical and anal dysplasias, other dysplasias, severe dysplasias, hyperplasias, atypical hyperplasias, and neoplasias.
  • cancer and “cancerous” as used herein refers to malignant tumors or describe the physiological condition characterized by unregulated cell growth.
  • polymer-drug conjugates of the present invention find use in the treatment and/or prophylaxis of cancer.
  • the polymer-drug conjugate of the present invention will generally be administered in the form of a pharmaceutical composition.
  • a pharmaceutical composition comprising a polymer-drug conjugate according to formula I and at least one pharmaceutically acceptable diluent, excipient and/or carrier.
  • treatment includes either therapeutic or prophylactic therapy.
  • composition comprising the polymer-drug conjugate of the invention may be in any suitable form depending upon the desired method of administering it to a patient.
  • the composition comprising polymer drug conjugates of the invention can be formulated to be administered orally, e.g. in the form of liquid dispersions or aqueous or oily suspensions or they can formulated for parenteral administration, for example for subcutaneous, intravenous, intramuscular, intrasternal, intraperitoneal, intradermal, transdermal or other infusion techniques.
  • the composition comprising the polymer drug conjugates of the invention can also be formulated for administration by inhalation in form of an aerosol or solution for administration with and inhaler or nebulizer.
  • the polymer-drug conjugates of the invention are preferably administered to a subject transdermally, subcutaneously, intranasally, intravenously, intramuscularly, intratumorally or via inhalation.
  • the most suitable route for administration in any given case will depend on the particular therapeutic agent present in the polymer-drug conjugate of the present invention, the subject, and the nature and severity of the disease and the physical condition of the subject.
  • the polymer-drug conjugates of the invention may be administered in combination, e.g. simultaneously, sequentially or separately, with one or more other therapeutically active compounds, which may be an anti-cancer agent or it is an immunomodulatory, antiviral, antiinfective, antimicrobial, antiinfective or anesthetic agent or combinations thereof.
  • one or more other therapeutically active compounds which may be an anti-cancer agent or it is an immunomodulatory, antiviral, antiinfective, antimicrobial, antiinfective or anesthetic agent or combinations thereof.
  • Said second therapeutic agent can be selected from the therapeutic agents listed above on the condition that it is different from the one present in the polymer-drug conjugate of the invention.
  • Embodiments are described herein as comprising certain features/elements. The disclosure also extends to separate embodiments consisting or consisting essentially of said features/elements.
  • the GFLG-MA linker was prepared according to the literature method described in K.Ulbrich et al., Journal of Controlled Release, 64, 2000, 63-79 .
  • Docetaxel was coupled with the GFLG-MA linker according to the literature method described in Ghandehari et al., Mol. Pharm., 2011, 8(4), 1090-1099 to give DTX-GFLG-MA.
  • Docetaxel (0.335g, 4.1 mmol), 4-(dimethylamino-) pyridine (DMAP, 0.049g, 4.0 mmol) and MA-GFLG-OH (0.188 g, 4.0 mmol) were dried under vacuum.
  • the reaction mixture was dissolved under nitrogen in anhydrous N, N-dimethylformamide (DMF, 5 mL), cooled with an ice bath (salt/ice) at ⁇ 0°C and diisopropylcarbodiimide (DIPC, 76 ⁇ L, 4.89 mmol) was added dropwise.
  • DIPC diisopropylcarbodiimide
  • reaction mixture was subsequently stirred for an hour before the ice bath was removed and the mixture was allowed to warm up to room temperature, stirred overnight and progress was monitored by thin layer chromatography (TLC, eluent dichloromethane (DCM): methanol (MeOH) (95:5)) for the disappearance of the starting material and the formation of MA-GFLG-Docetaxel.
  • DMF was removed under vacuum using rotary evaporator.
  • the product was purified by silica gel chromatography.
  • PEGMEMA Polyethylene glycol methyl ether methacrylate
  • DTX-GFLG-MA Polyethylene glycol methyl ether methacrylate
  • the inventors prepared 50 kDa and 85 kDa PEGMEMA-DTX polymer-drug conjugates and subjected them to pharmacokinetic testing.
  • PEGMEMA-DTX conjugates having 50kDa and 85 kDa molecular weight were subjected to pharmacokinetic testing and its pharmacokinetic profile was compared with that of free DTX.
  • Pharmacokinetic parameters for total DTX were calculated using the plasma total DTX concentration values of polymer drug conjugates and free DTX.
  • Half-life, volume of distribution (VD ⁇ ), clearance (CL), and total area under the curve (AUC total) were calculated.
  • HPMA-GFLG-DTX polymers having molecular weight of 52 kDa and 85 kDa according to the known prior art methods disclosed in Ghandehari et al., Mol. Pharm., 2011, 8(4), 1090-1099 .
  • HPMA-GFLG-DTX polymer was prepared without RGDfK targeting group.
  • Table 1 Pharmacokinetic parameters of PEGMEMA-GFLG-DTX conjugates, HPMA-GFLG-DTX conjugates and free DTX Half Life (p)(hour) VDp (mL) CL (mL/hr) AUC total (ug/mL.hr) Free DTX 3.12 ⁇ 0,88 664.1 ⁇ 258.1 140.4 ⁇ 42.1 10 ⁇ 3 HPMA 52kDa-DTX 11.99 ⁇ 0.37 102.5 ⁇ 13.8 5.9 ⁇ 0.7 241 ⁇ 32 HPMA 85kDa-DTX 16.24 ⁇ 4.40 60.2 ⁇ 11.1 2.6 ⁇ 0.2 525 ⁇ 57 PEGMEMA 50kDa-DTX 14.62 ⁇ 0.54 20.2 ⁇ 1.9 1.0 ⁇ 0.1 1357 ⁇ 109 PEGMEMA 85kDa-DTX 12.10 ⁇ 0.35 10.0 ⁇ 0.2 0.6 ⁇ 0.0 2370 ⁇ 106
  • both PEGMEMA-DTX conjugates have superior pharmacokinetic properties compared to the free therapeutic agent and HPMA-DTX conjugate. This result is indicative of the fact that the polymer-drug conjugate of the present invention provides a superior polymer-drug conjugate having longer half-life, lower clearance and larger AUC with respect to free DTX and DTX bound to HPMA polymer.
  • Figure 1 is a graph showing percent hemogram values of PEGMEMA-DTX conjugates and free DTX.

Description

  • This invention relates to polymer drug conjugates according to formula I, methods of preparing said polymer-drug conjugates and their use for treatment of diseases such as cancer.
    • BACKGROUND OF THE INVENTION
  • Chemotherapy agents used for treatment of cancer are mostly cytotoxic. These agents may accumulate in the tissues of the body in addition to the targeted area, which in turn causes lowered therapeutic benefit and undesired distribution of the drug throughout healthy body tissues. The uncontrolled distribution of these agents throughout the body causes severe side effects to the patient.
  • Due to distribution of the chemotherapy agents to the entire body including the healthy tissue, the amount of chemotherapy agent reaching the tumor tissue is very low despite the high overall toxicity caused by the given dose. This situation leads to low therapeutic benefit for the patient. Moreover, chemotherapy agents have low solubility which makes them difficult to formulate and administer to the patient.
  • In order to address the abovementioned problems, drug delivery systems, which can deliver the drug to targeted areas of the body, are developed. For example in some approaches of cancer treatment, these systems make use of the enhanced permeability and retention effect (EPR) which implies that drug carriers having high molecular weight and large hydrodynamic volume accumulate in solid tumors and this, in turn leads to passive targeting of the drug molecule to the tumor tissue and minimize the damage of the chemotherapy agents to healthy tissue.
    • TECHNICAL FIELD OF THE INVENTION
  • There are a number of polymers that can be used for preparing polymer-drug conjugates.
  • US 6310039 disclose conjugates of transferrin, albumin and polyethylene glycol and cytostatic compounds such as doxorubicin, daunorubicin, epirubicin etc. In this document, the drug molecules are attached to the end groups of a polyethylene glycol polymer. One drawback of these systems is that they have limited functional groups for drug conjugation as a result they have a low drug percentage on the final drug polymer conjugate. Furthermore, aggregation is another phenomenon that is hard to deal with for this type of polymer drug conjugates.
  • For example, WO 1998/056424 discloses a polymer drug conjugate wherein dextrin forms the backbone of the polymer and the drug molecules are either directly or indirectly bound to the polymer backbone.
  • Another example is WO 2007/028347 that discloses a method for preparing a polymeric conjugate of the doxorubicine, which is an anti-cancer drug molecule. The document teaches use of N-(2-hydroxy propyl) methacrylamide (HPMA) monomer for formation of the polymer.
  • US 2003/0215395 discloses a cationic polymer such as poly(L-lycine), polyethylene imine and chitosan conjugated to a drug with a linker.
  • Kopecek, J. et. al., European Journal of Pharmaceutics and Biopharmaceutics, 50, 2000, 61-81 discloses HPMA based polymer drug conjugates where GFLG is used as a cleavable linker and doxorubicin is used as a therapeutic agent. For this conjugate HPMA was preferred because it is hydrophilic, biocompatible and as a result a water soluble polymeric drug carrier is obtained.
  • The above systems employ drug molecules attached to the polymer backbone via a linker aiming cleavage of the linker after the polymer-drug conjugate reaches its target tissue, thus releasing the drug molecule at the target site. However, the disadvantage of these systems is that the cleavable linker between the drug and the polymer cleaves in the blood stream and releases the drug molecule before it reaches its target tissue.
  • In light of the abovementioned state of the art, there is a need for a new polymer-drug conjugate, which is less toxic and has desirable pharmacokinetic profile.
  • Another object of the present invention is to provide a polymer-drug conjugate which addresses the problem of drug cleavage before the polymer drug conjugate reaches the targeted tissue.
  • The inventors have surprisingly found that a polymer-drug conjugate according to present invention has considerably higher circulation time, provides selective distribution of the active agent to the targeted tissues, has lower volume of distribution, lower clearance, and higher maximum concentration (Cmax) and higher total area under the curve (AUC total) values.
    • BRIEF DESCRIPTION OF THE INVENTION
  • Present invention relates to a polymer-drug conjugate as shown in Formula I for delivery of therapeutic agents comprising a (meth)acrylate based polymer backbone characterized in that the polymer comprises at least two types of side chains wherein one of the side chains is a PEG chain such as -COOCH2CH2(OCH2CH2)nOR3 wherein n is a natural number between 1-200 and R3 is selected from a group comprising H or -CH3 and the other side chain is comprising at least one therapeutic agent covalently bonded to a cleavable linker.
    Figure imgb0001
  • In other words, the invention relates to a polymer-drug conjugate of Formula I, wherein; R1 and R2 are independently selected from H or -CH3; R3 is selected from -H or -CH3; x is a natural number between 1-140; y is a natural number between 1-40; n is a natural number between 1-200 and L is a cleavable linker and D is at least one therapeutic agent, Z is selected from N or O; A is an end group that is optionally a polymerization initiator or a fragment thereof ;
    B is an end group that is optionally a polymerization initiator or a fragment thereof
  • The inventors have surprisingly found that in addition to overcoming the disadvantages of the prior art drug delivery systems comprising polymer-drug conjugates; the polymer of the present invention has reduced accumulation in the other organs due to the presence of biodegradable PEG side chains. This, in turn, provides a polymer-drug conjugate that has lower toxicity.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The term "polymer-drug conjugate" refers to a polymeric structure having a therapeutic agent covalently attached to the polymer.
  • The terms "polymeric backbone" and "polymer backbone" can be used interchangeably and refer to a polymer chain having side chains or pendant groups. For example, a side chain may have an oligo ethylene glycol unit and a pendant group may be bearing one therapeutic agent or any other group that can be utilized to attach a therapeutic and/or diagnostic agent or a targeting group.
  • The term "acrylate" refers to derivatives of acrylic acids. These derivatives include the parent acid (CH2CHCO2H) and esters, thus the term "acrylate based" defines functional groups having any of the abovementioned acrylate derivatives.
  • The term "methacrylate" refers to derivatives of methacrylic acids. These derivatives include the parent acid (CH2C(CH3)CO2H) and esters. Thus the term "methacrylate based" defines functional groups having any of the abovementioned methacrylate derivatives.
  • The term "(meth)acrylate" refers to the terms "acrylate" and "methacrylate". Thus, the term "(meth)acrylate" can be used interchangeably with "acrylate" and "methacrylate" and comprises all features of these terms as described above. The term "(meth)acrylate" should be construed to mean "methacrylate and/or acrylate"
    Throughout the text, the term "the polymer-drug conjugate of the invention" should be construed to mean "a polymer-drug conjugate according to formula I" or "a polymer-drug conjugate of formula I" or "formula I" and these terms can be used interchangeably.
  • The term "PEG" refers to a polyether compound having the structure of H-(O-CH2-CH2)n-OR3, n being a natural number between 1-200 and R3 selected from H or -CH3. PEG is defined as an oligomer or polymer of ethylene oxide. The terms "PEG", "polyethylene glycol", "polyethylene oxide", "PEG", "polyoxyethylene" and "POE" refer to the same structure and may be used interchangeably within this text.
  • As shown by formula I the polymer-drug conjugate of the invention comprises PEG side chains. The side chains provide important physicochemical properties to the polymer-drug conjugate of the invention and leads to a polymer-drug conjugate that has better physicochemical properties in comparison to the conjugates that does not have said side chains.
  • As mentioned above "L" in formula I denotes a cleavable linker. The term "Cleavable linker" refers to a group that spatially separates drug or a targeting group from the carrier molecule. The terms "linker", "L" and "cleavable linker" refer to the same entity and can be used interchangeably.
  • Herein, the term "short peptide" should be construed to mean a peptide chain comprising 1-50 aminoacids, preferably 2-40 aminoacids and most preferably 2-30 aminoacids.
  • In one embodiment R1=H, R2=H, R3=H; In another embodiment Ri=H, R2=H, R3= -CH3; In another embodiment Ri=H, R2= -CH3, R3=H; In another embodiment Ri=H, R2= -CH3, R3=-CH3; In another embodiment R1=-CH3, R2= H, R3=H; In another embodiment R1=-CH3, R2= H, R3=-CH3; In another embodiment R1=-CH3, R2= -CH3, R3=H; In another embodiment R1=-CH3, R2= - CH3, R3= -CH3.
  • The term "random copolymer" refers to a copolymer wherein the monomers forming the copolymer follow in any order. The term "block copolymer" refers to a copolymer wherein all of one type of monomer is grouped together and the all of the other type of monomers are grouped together. The polymer-drug conjugates of the invention can be in the form of block copolymer or random copolymers. The polymer-drug conjugates of the invention are in the form of random copolymer.
  • The linkers are cleavable so that the therapeutic agent can be released, for example, under reducing conditions, oxidizing conditions or by hydrolysis of an ester, amide, hydrazide, or similar linkage that forms the covalent bond between the linker and the therapeutic agent. Additionally, the type of linker may augment the selective cytotoxicity (and thus improve the therapeutic index) aspect by permitting selective release of the therapeutic agent adjacent to or inside the cell.
  • Said cleavable linker can be any hydrocarbon or substituted hydrocarbon based compound which is capable of dissociating under physiological conditions. In a preferred embodiment the linker can be selected from compounds that are cleaved under the acidic conditions of the tumor (such as any C1-C10 substituted hydrocarbon comprising an acetal or an ester functional group) or with the help of the overexpressed enzymes present in the intercellular or intracellular matrix of the tumor cells.
  • The linker can be any sort of entity capable of binding to both the polymer backbone and to the drug, such as, a poly(ethylene glycol), an amino acid, poly(amino acid) (e.g. a peptide or oligopeptide), or polypeptide (e.g. a protein), such that one end of it is capable of forming a covalent bond with the polymer backbone and the other end of it is capable of forming a covalent bond with the therapeutic agent. The linkers may also include short peptides with specific peptide sequences that are cathepsin B labile, such as Gly-Phe-Leu-Gly (SEQ ID NO: 1) also denoted as GFLG or Val-Cit or Phe-Lys or Val-Ala or Ala-Leu-Ala-Leu (SEQ ID NO: 2)
  • The linker can also be a C1-C10 hydrocarbon or a C1-C10 substituted or hetero substituted hydrocarbon such that it comprises a functional group that dissociates under physiological conditions, such as an acetal, ester, imine, amide, disulfide, carbonate, carbamate, hydrazone.
  • The term "C1-C10 hydrocarbon" refers to a hydrocarbon chain having 1 to 10 C atoms in the backbone.
  • The term "C1-C10 substituted hydrocarbon" refers to a hydrocarbon chain having 1 to 10 C atoms in the backbone wherein one or more of its hydrogen atoms replaced by atoms of groups of other elements such as alcohol, amine, carboxyl, thiol etc.
  • The term "C1-C10 heterosubstituted hydrocarbon" refers to a hydrocarbon chain having 1 to 10 C atoms in the backbone wherein at least one of the C atoms is substituted with an atom other than C such as nitrogen, oxygen, phosphorus, sulfur or a halogen atom. These substituents include but not limited to lower alkoxy such as methoxy, ethoxy, butoxy; ethers; acetals; ketals; esters; hetroaryl; heterocyclic; hydroxyl; protected hydroxyl; acyl; acyloxy; amino; amido; imine, disulfide, carbonate, carbamate, hydrozone, hydrazine.
  • In an embodiment of the invention, the linker (L) is GFLG. In an embodiment of the invention, the linker is Val-Cit. In an embodiment of the invention, the linker is Phe-Lys. In an embodiment of the invention, the linker is Val-Ala. In an embodiment of the invention, the linker is Ala-Leu-Ala-Leu.
  • In an embodiment of the invention, the linker is a C1-C10 hetero substituted hydrocarbon comprising at least one disulfide functional group. In an embodiment of the invention the linker is a C1-C10 hetero substituted hydrocarbon comprising at least one acetal functional group. In an embodiment of the invention the linker is a C1-C10 hetero substituted hydrocarbon comprising at least one ester functional group. In an embodiment of the invention the linker is a C1-C10 hetero substituted hydrocarbon comprising at least one imine functional group. In an embodiment of the invention the linker is a C1-C10 hetero substituted hydrocarbon comprising at least one amide functional group. In an embodiment of the invention the linker is a C1-C10 hetero substituted hydrocarbon comprising at least one carbonate functional group. In an embodiment of the invention the linker is a C1-C10 hetero substituted hydrocarbon comprising at least one carbamate functional group. In an embodiment of the invention the linker is a C1-C10 hetero substituted hydrocarbon comprising at least one hydrazone functional group.
  • In another embodiment of the invention the linker may comprise a C1-C10 substituted or hetero substituted hydrocarbon comprising two or more functional groups selected from the group comprising acetal, ester, imine, amide, disulfide, carbonate, carbamate, hydrazone.
  • In another embodiment of the invention the linker may be a combination of a C1-C10 substituted hydrocarbon comprising at least one functional group selected from the group comprising acetal, ester, imine, amide, disulfide, carbonate, carbamate, hydrazone and a peptide chain selected from the group comprising GFLG, Val-Cit or Phe-Lys or Val-Ala or Ala-Leu-Ala-Leu.
  • The term "therapeutic agent" refers to any compound that is suitable for use in treatment of a disease. The terms "therapeutic agent", "chemotherapy agent", "anticancer agent" and "antineoplastic agent" all refer to the compounds suitable for use in treatment of a disease and these terms can be used interchangeably. In one embodiment, the disease is cancer.
  • Additionally, a "therapeutic agent" also refers to any agent that is suitable for use in treating of a disease, for example cancer. Any therapeutic agent which can be directly or indirectly attached to the polymer-drug conjugate of the invention can be used. U.S. Patent Nos 6 6,342,221 also describe agents related to anticancer agents and this document is incorporated herein by reference. Anticancer agents can be classified as but are not limited to, chemotherapeutic agents, cytotoxins, antimetabolites, alkylating agents, protein kinase inhibitors, anthracyclines, antibiotics, antimitotic agents (e.g. antitubulin agents), corticosteroids, radiopharmaceuticals, and proteins (e.g. cytokines, enzymes, or interferons). Specific examples of anticancer agents are for example, docetaxel, gemcitabine, imatinib, 5-fluorouracil, 9-aminocamptothecin, amine-modified geldanamycin, doxorubicin, paclitaxel, procarbazine, hydroxyurea, meso e-chlorin, cisplatin and radionuclides (e.g 1-131, Y-90, In-111, and Tc-99m). There are many other anticancer agents known in the art and many continue to be developed, those agents are also included within the scope of this invention.
  • The therapeutic agent(s) can also be selected from a sub group comprising, but not limited to, nucleoside analogs, antifolates, other metabolites, topoisomerase I inhibitors, anthracyclines, podophyllotoxins, taxanes, vinca alkaloids, alkylating agents, platinum compounds, antihormones, radiopharmaceutics, monoclonal antibodies, tyrosine kinase inhibitors, mammalian target of rapamycin (mTOR) inhibitors, retinoids, immunomodulatory agents, histonedeacetylase inhibitors and other agents.
  • Nucleoside analogs can be selected from a group comprising, but not limited to, azacitidine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabine, fluorouracil (5-FU), gemcitabine, mercaptopurine, nelarabine, pentostatin, tioguanine, trifluridine, tipiracil.
  • Antifolates can be selected from a group comprising, but not limited to, methotrexate, pemetrexed, pralatrexed, raltitrexed. Other metabolites can be selected from a group comprising, but not limited to, hydroxycarbamide. Topoisomerase I inhibitors can be selected from a group comprising, but not limited to, irinotecan and topotecan. Anthracyclines can be selected from a group comprising, but not limited to, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, valrubicin. Podophyllotoxins can be selected from a group comprising, but not limited to, etoposide and teniposide. Taxanes can be selected from a group comprising, but not limited to, cabazitaxel, docetaxel, paclitaxel. Vinca alkaloids can be selected from a group comprising, but not limited to, vinblastine, vincristine, vindesine, vinflunine, vinorelbine. Alkylating agents can be selected from a group comprising, but not limited to, bendamustine, chlorambucil, dacarbazine, melphalan, streptozotocin, trabectedin. Antihormone compounds can be selected from a group comprising, but not limited to, abiraterone, bicalutamide, cyproterone, degarelix, exemestane, fulvestrant, goserelin, histrelin, leuprolide, mifepristone, triptorelin. Tyrosine kinase inhibitors can be selected from a group comprising, but not limited to, afatinib, axitinib, bosutinib, cobimetinib, crizotinib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, osimertinib, pazopanib, ruxolitinib, sunitinib, vandetanib. Mammalian target of rapamycin (mTOR) inhibitors can be selected from a group comprising, but not limited to everolimus, temsirolimus. Retinoids can be selected from a group comprising, but not limited to, alitretinoin, bexarotene, isotretinoin, tamibarotene, tretinoin. Immunomodulatory agents can be selected from a group comprising, but not limited to, lenalidomide, pomalidomide, thalidomide. Histone deacetylase inhibitors can be selected from a group comprising, but not limited to, belinostat, panobinostat, valproate, vorinostat. Other agents can be selected from a group comprising, but not limited to, anagrelide, ceritinib, dabrafenib, idelalisib, ibrutinib, palbociclib, vemurafenib, bleomycin, bortezomib, dactinomycin, eribulin, estramustine, ixabepilone, mitomycin, procarbazine, alectinib, fluxymesterone, iobenguane, imiguimod, interferon, ixazomib, lanreotide, lentinan, octreotide, omacetaxine, tegafur, gimerazil, oteracil, uracil, combretastatin, chloroquine.
  • In a preferred embodiment of the invention the therapeutic agent(s) is selected from taxanes, antifolates, tyrosine kinase inhibitors, anthracyclines, nucleoside analogs or other agents. Most preferably the therapeutic agent(s) is selected from a group comprising docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, Fluorouracil (5-FU), 5'-Deoxy 5-Fluorocytidine (5'-DFCR), lapatinib and any of the therapeutic agents listed above. As such the therapeutic agents
  • Herein the term "agent(s)" refer to at least one or more therapeutic agents.
  • In an embodiment of the invention the therapeutic agent is docetaxel. In an embodiment of the invention the therapeutic agent is pemetrexed. In an embodiment of the invention the therapeutic agent is chloroquine. In an embodiment of the invention the therapeutic agent is combretastatin. In an embodiment of the invention the therapeutic agent is gemcitabine. In an embodiment of the invention the therapeutic agent is doxorubicine. In an embodiment of the invention the therapeutic agent is 5-FU. In an embodiment of the invention the therapeutic agent is 5'-Deoxy 5-Fluorocytidine (5'-DFCR). In an embodiment of the invention the therapeutic agent is lapatinib.
  • In an embodiment of the invention the therapeutic agent is a combination of two or more therapeutic agents selected from the group comprising docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, 5-FU, 5'-Deoxy 5-Fluorocytidine (5'-DFCR) and lapatinib and any other agents listed above. As such therapeutic agent(s) that are a combination of two or more therapeutic agents can be selected from the main groups or specific members of the main groups listed above.
  • The therapeutic agent can be present in an amount in between 1% to 40% by weight of the polymer-drug conjugate, preferably in an amount between 2% to 35% by weight of the drug-polymer conjugate and most preferably in an amount between 3% to 30% by weight of the drug-polymer conjugate. The therapeutic agent can be present in an amount in the range of for example; 4% to 25% or 5% to 24% or 6% to 23% or 7% to 22% or 8% to 20% by weight of the drug-polymer conjugate.
  • The term "end group" refers to functionalities or constitutional units that are at the extremity of a polymer. The end groups shown as A and B can be identical to or different from one another.
  • A and B can optionally be a polymerization initiator or a fragment thereof. Particularly when an initiator is used in the polymerization reaction, the initiator fragment may stay as an end group to the polymer. The initiator used herein, may be any material suitable for initiating the polymerization reaction known in the art.
  • In one embodiment, A and/or B is selected from the group consisting of 4,4'-Azobis(4-cyanovaleric acid), 4,4'-Azobis(4-cyanovaleric acid), 1,1'-Azobis(cyclohexanecarbonitrile), 2,2'-Azobis(2-methylpropionamidine) dihydrochloride, 2,2'-Azobis(2-methylpropionitrile) (also known as AIBN), Ammonium persulfate, hydroxymethanesulfinic acid monosodium salt dihydrate, potassium persulfate, sodium persulfate, tert-Butyl hydroperoxide, tert-Butyl peracetate, Cumenehydroperoxide, 2,5-Di(tert-butylperoxy)-2,5-dimethyl-3-hexyne, Dicumyl peroxide, 2,5-Bis(tert-butylperoxy)-2,5-dimethylhexane, 1,1-Bis(tert-butylperoxy)-3,3,5-trimethylcyclohexane, 1,1-Bis(tert-amylperoxy)cyclohexane, Benzoyl peroxide, 2-Butanone peroxide, tert-Butyl peroxide, Di-tert-amyl peroxide, Lauroyl peroxide, tert-Butyl peroxybenzoate, tert-Butylperoxy 2-ethylhexyl carbonate, tert-Butyl hydroperoxide, 2-Azidoethyl 2-bromoisobutyrate, Bis[2-(2-bromoisobutyryloxy)undecyl] disulfide, Bis[2-(2'-bromoisobutyryloxy)ethyl]disulfide, 2-Bromoisobutanoic acid N-hydroxysuccinimide ester, 2-Bromoisobutyric anhydride, α-Bromoisobutyryl bromide, 2-(2-Bromoisobutyryloxy)ethyl methacrylate, tert-Butyl α-bromoisobutyrate, 3-Butynyl 2-bromoisobutyrate, Dipentaerythritolhexakis(2-bromoisobutyrate), Dodecyl 2-bromoisobutyrate, Ethyl α-bromoisobutyrate, Ethylene bis(2-bromoisobutyrate), 2-Hydroxyethyl 2-bromoisobutyrate, 1-(DL-1,2-Isopropylideneglyceryl) 2-bromoisobutyrate, Methyl α-bromoisobutyrate, Octadecyl 2-bromoisobutyrate, Pentaerythritoltetrakis(2-bromoisobutyrate), 1-(Phthalimidomethyl) 2-bromoisobutyrate, Poly(ethylene glycol) bis(2-bromoisobutyrate), Propargyl 2-bromoisobutyrate, 1,1,1-Tris(2-bromoisobutyryloxymethyl)ethane, 10-Undecenyl 2-bromoisobutyrate, N-tert-Butyl-O-[1-[4-(chloromethyl)phenyl]ethyl]-N-(2-methyl-1-phenylpropyl)hydroxylamine, N-tert-Butyl-N-(2-methyl-1-phenylpropyl)-O-(1-phenylethyl)hydroxylamine, TEMPO, TEMPO methacrylate, 2,2,5-Trimethyl-4-phenyl-3-azahexane-3-nitroxide, 3,5-Bis(2-dodecylthiocarbonothioylthio-1-oxopropoxy)benzoic acid, 3-Butenyl 2-(dodecylthiocarbonothioylthio)-2-methylpropionate, 4-Cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanoic acid, 4-Cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanol, Cyanomethyl dodecyl, Cyanomethyl [3-(trimethoxysilyl)propyl] trithiocarbonate, 2-Cyano-2-propyl dodecyl trithiocarbonate, S,S-Dibenzyl trithiocarbonate, 2-(Dodecylthiocarbonothioylthio)-2-methylpropionic acid, 2-(Dodecylthiocarbonothioylthio)-2-methylpropionic acid, 3-azido-1-propanol ester, 2-(Dodecylthiocarbonothioylthio)-2-methylpropionic acid N-hydroxysuccinimide ester, 2-(Dodecylthiocarbonothioylthio)-2-methylpropionic acid pentafluorophenyl ester, 2-(Dodecylthiocarbonothioylthio)propionic acid, Methyl 2-(dodecylthiocarbonothioylthio)-2-methylpropionate, Pentaerythritol tetrakis[2-(dodecylthiocarbonothioylthio)-2-methylpropionate], Phthalimidomethyl butyl trithiocarbonate, 1,1,1-Tris[(dodecylthiocarbonothioylthio)-2-methylpropionate]ethane, benzyl benzodithioate, Cyanomethyl benzodithioate, 4-Cyano-4-(phenylcarbonothioylthio)pentanoic acid, 4-Cyano-4-(phenylcarbonothioylthio)pentanoic acid N-succinimidyl ester, 2-Cyano-2-propyl benzodithioate, 2-Cyano-2-propyl 4-cyanobenzodithioate, Ethyl 2-(4-methoxyphenylcarbonothioylthio)acetate, Ethyl 2-methyl-2-(phenylthiocarbonylthio)propionate, Ethyl 2-(phenylcarbonothioylthio)-2-phenylacetate, Ethyl 2-(phenylcarbonothioylthio)propionate, 1-(Methoxycarbonyl)ethyl benzodithioate, 2-(4-Methoxyphenylcarbonothioylthio)ethanoic acid, 2-Nitro-5-(2-propynyloxy)benzyl, 4-cyano-4-(phenylcarbonothioylthio)pentanoate, 2-(Phenylcarbonothioylthio)propanoic acid, 2-Phenyl-2-propyl benzodithioate, Cyanomethyl methyl(4-pyridyl)carbamodithioate, Cyanopropan-2-yl N-methyl-N-(pyridin-4-yl)carbamodithioate, Methyl 2-[methyl(4-pyridinyl)carbamothioylthio]propionate, 1-Succinimidyl-4-cyano-4-[N-methyl-N-(4-pyridyl)carbamothioylthio]pentanoate or any fragment of the initiators listed herein.
  • The term "fragment" as used herein refers to compounds that form due to breaking of one or more of the covalent bonds forming the initiator molecule.
  • In an embodiment A and B are both fragments of a polymerization initiator however they are structurally different from one another. In other words, A and B are different fragments of the same initiator. In another embodiment A and B are both fragments of a polymerization initiator and they have the same chemical structure.
  • In some of the preferred embodiments, the polymer drug conjugate of invention comprise one or more of the following;
    • GFLG as the linker (L) and a therapeutic agent selected from the group docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, 5-FU, 5'-Deoxy 5-Fluorocytidine (5'-DFCR) and lapatinib.
    • Val-Cit as the linker (L) and a therapeutic agent selected from the group docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, 5-FU, 5'-Deoxy 5-Fluorocytidine (5'-DFCR) and lapatinib.
    • Phe-Lys as the linker (L) and a therapeutic agent selected from the group docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, 5-FU, 5'-Deoxy 5-Fluorocytidine (5'-DFCR) and lapatinib.
    • Val-Ala as the linker (L) and a therapeutic agent selected from the group docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, 5-FU, 5'-Deoxy 5-Fluorocytidine (5'-DFCR) and lapatinib.
    • Ala-Leu-Ala-Leu as the linker (L) and a therapeutic agent selected from the group docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, 5-FU, 5'-Deoxy 5-Fluorocytidine (5'-DFCR) and lapatinib.
    • A C1-C10 hetero substituted hydrocarbon comprising at least one disulfide functional group as the linker (L) and a therapeutic agent selected from the group docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, 5-FU, 5'-Deoxy 5-Fluorocytidine (5'-DFCR) and lapatinib.
    • A C1-C10 hetero substituted hydrocarbon comprising at least one acetal functional group as the linker (L) and a therapeutic agent selected from the group docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, 5-FU, 5'-Deoxy 5-Fluorocytidine (5'-DFCR) and lapatinib.
    • A C1-C10 hetero substituted hydrocarbon comprising at least one ester functional group as the linker (L) and a therapeutic agent selected from the group docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, 5-FU, 5'-Deoxy 5-Fluorocytidine (5'-DFCR) and lapatinib.
    • A C1-C10 hetero substituted hydrocarbon comprising at least one imine functional group as the linker (L) and a therapeutic agent selected from the group docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, 5-FU, 5'-Deoxy 5-Fluorocytidine (5'-DFCR) and lapatinib.
    • A C1-C10 hetero substituted hydrocarbon comprising at least one amide functional group as the linker (L) and a therapeutic agent selected from the group docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, 5-FU, 5'-Deoxy 5-Fluorocytidine (5'-DFCR) and lapatinib.
    • A C1-C10 hetero substituted hydrocarbon comprising at least one carbonate functional group as the linker (L) and a therapeutic agent selected from the group docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, 5-FU, 5'-Deoxy 5-Fluorocytidine (5'-DFCR) and lapatinib.
    • A C1-C10 hetero substituted hydrocarbon comprising at least one carbamate functional group as the linker (L) and a therapeutic agent selected from the group docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, 5-FU, 5'-Deoxy 5-Fluorocytidine (5'-DFCR) and lapatinib.
    • A C1-C10 hetero substituted hydrocarbon comprising at least one hydrazone functional group as the linker (L) and a therapeutic agent selected from the group docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, 5-FU, 5'-Deoxy 5-Fluorocytidine (5'-DFCR) and lapatinib.
    • A C1-C10 substituted or hetero substituted hydrocarbon comprising two or more functional groups selected from the group comprising acetal, ester, imine, amide, disulfide, carbonate, carbamate, hydrazone as the linker (L) and a therapeutic agent selected from the group docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, 5-FU, 5'-Deoxy 5-Fluorocytidine (5'-DFCR) and lapatinib.
    • A combination of a C1-C10 substituted hydrocarbon comprising at least one functional group selected from the group comprising acetal, ester, imine, amide, disulfide, carbonate, carbamate, hydrazone and a peptide chain selected from the group comprising GFLG, Val-Cit, Val-Ala, Ala-Leu-Ala-Leu or Phe-Lys as the linker (L) and a therapeutic agent selected from the group docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, 5-FU, 5'-Deoxy 5-Fluorocytidine (5'-DFCR) and lapatinib.
  • The measurement of the amount of drug in the polymer conjugate of the invention is made by using conventional techniques well-known in the art, for example by calculation of the drug ratio from an 1H-NMR of the polymer-drug conjugate.
  • In another embodiment the polymer-drug of the invention has an average molecular weight in between 20 kDa to 300 kDa, preferably between 30 Da to 270 kDa, most preferably between 40 kDa to 250 kDa.
  • Molecular weight of the polymer-drug conjugate of the invention is determined by using conventional techniques known in the art for example by using gel permeation chromatography (GPC).
  • Another embodiment of the invention is a method (Method I) for preparation of the polymer-drug conjugate of the invention (formula I) which comprises polymerization of PEG (meth)acrylate monomer (Formula II)
    Figure imgb0002
     and at least one type of (meth)acrylate-L-D monomer (Formula IIIa)
    Figure imgb0003
     wherein R1 and R2 are independently selected from H or -CH3, R3 is selected from -H or -CH3, L is a cleavable linker, D is at least one therapeutic agent and n is a natural number between 1-200
  • In another aspect, a method (Method II) for preparation of the polymer-drug conjugate of the invention (formula I) comprises (i) polymerization of PEG (meth)acrylate monomer (Formula II) and (meth)acrylate-L monomer (Formula IIIb)
    Figure imgb0004
     wherein R1 and R2 are independently selected from H or -CH3, R3 is selected from -H or -CH3, L is a cleavable linker and n is a natural number between 1-200 to give a copolymer as shown in formula IV
    Figure imgb0005
     wherein x is a natural number between 1-100 and y is a natural number between 1-100, Z is selected from O or NH, A is an end group that is optionally a polymerization initiator or a fragment thereof , B is an end group that is optionally a polymerization initiator or a fragment thereof , and then (ii) reacting formula IV with at least one type of therapeutic agent (D) to give polymer conjugate shown in formula I.
  • In another aspect, a method (method III) for preparation of the polymer-drug conjugate of the invention (formula I) comprises (i) polymerization of PEG (meth)acrylate monomer shown with Formula II and (meth)acrylate monomer shown with Formula IIIc
    Figure imgb0006
     wherein n is a natural number between 1-200 and, R1 and R2 are independently selected from H or -CH3, R3 is selected from -H or -CH3 , R4 is selected from carbonyl activating groups such as perfluorophenoxy, maleimide, carbonate, thiazolidone-2-thione, N-oxybenzotriazole, imidazolyl, o/p-nitrophenol, pentachloro-phenol, N-hydroxysuccinimide, acetates, formates, 2,3,5-trichlorophenol, 8-hydroxyquinoline, -OCH3, -OCH2CH3, Cl, F, Br, H, -SH, -NH2, -NHR5 or - ORs wherein R5 is C1-C10 saturated or unsaturated hydrocarbon to give a copolymer as shown in formula V
    Figure imgb0007
     wherein x is a natural number between 1-100 and y is a natural number between 1-100, Z is selected from O or NH, A is an end group that is optionally a polymerization initiator or a fragment thereof , B is an end group that is optionally a polymerization initiator or a fragment thereof and then (ii) reacting formula V with at least one type of therapeutic agent attached to a linker (L-D) to give polymer conjugate of formula I.
  • Herein the term "carbonyl activating group" refers to leaving group of a carboxyl derivative that is easily replaced by an incoming nucleophile.
  • In another aspect, a method (method IV) for preparation of the polymer-drug conjugate of the invention (formula I) comprises (i) polymerization of PEG (meth)acrylate monomer (Formula II) and (meth)acrylate monomer (Formula IIIc); wherein n is a natural number between 1-200 and, R1 and R2 are independently selected from H or -CH3, R3 is selected from -H or -CH3, R4 is selected from carbonyl activating groups such as perfluorophenoxy, maleimide, carbonate, thiazolidone-2-thione, N-oxybenzotriazole, imidazolyl, o/p-nitrophenoxy, pentachloro-phenoxy, N-hydroxysuccinimide, acetates, formates, 2,3,5-trichlorophenol, 8-hydroxyquinoline, -OH, -OCH3, -OCH2CH3, Cl, F, Br, H, -SH, -NH2, -NHR5 or -OR5 wherein R5 is C1-C10 saturated or unsaturated hydrocarbon to give a copolymer as shown in formula V; wherein x is a natural number between 1-100 and y is a natural number between 1-100, Z is selected from O or NH, A is an end group that is optionally a polymerization initiator or a fragment thereof or A may be null, B is an end groups that is optionally a polymerization initiator or a fragment thereof or B may be null and (ii) reacting formula V with a linker (L) to give a copolymer as shown in formula IV; wherein n, x, y, R1, R2 and R3 are as described above and (iii) reacting formula IV with at least one type of therapeutic agent (D) to give polymer conjugate shown in formula I.
  • Within this document the terms "at least one therapeutic agent" and "at least one type of therapeutic agent" are used interchangeably and refer to use of structurally different therapeutic agents or in other words refer to attachment of one or more such as two, three, four etc. different therapeutic agents onto the polymers according to present invention, as such the terms does not refer to quantitative amount used in the polymer structure. Similarly, the term "at least one type of (meth)acrylate-L-D monomer" refers to monomer structures having one or more such as two, three or four etc. different therapeutic agents as molecule D.
  • In another aspect, the invention relates to polymer-drug conjugate of formula I prepared by any one of the methods I, II, III or IV. Polymer-drug conjugate of formula I prepared by methods I, II, III or IV has a random copolymer structure which has advantageous technical effects.
  • In one embodiment, PEG (meth)acrylate (Formula II) is preferably selected from a group comprising; polyethylene glycol methyl ether methacrylate, polyethylene glycol methacrylate, polyethylene glycol methyl ether acrylate, and poly ethylene glycol acrylate. In a preferred embodiment of the invention, polyethylene glycol methyl ether methacrylate, wherein R1 and R3 are both-CH3, is used.
  • In an embodiment of the invention PEG (meth)acrylate (Formula II) has an average molecular weight in between 200-2000 g/mol, preferably between 250-1500 g/mol, most preferably 300-1100 g/mol is used.
  • The cleavable linker according to present invention can be obtained from commercial sources or may be prepared according to known methods provided in literature.
  • As disclosed above, methods for preparing the polymer drug conjugate of formula I (Method I, II, III and IV) comprise at least one polymerization step, wherein monomers formula II and monomers of formula IIIa or IIIb or IIIc are polymerized. In an embodiment of the invention, these polymerization steps further comprise an initiator and/or a solvent.
  • The polymer-drug conjugate of the invention can be prepared by any of the known polymerization methods. Any suitable initiators and/or catalysts known in the art can be used for the preparation of the polymer-drug conjugate of the present invention. Where a polymerization initiator is used, the initiator or a fragment thereof may be present in the resulting polymer-drug conjugate.
  • The polymer backbone of the polymer-drug conjugate of the invention can be obtained by for example bulk polymerization, solution polymerization and/or suspension polymerization techniques known in the art.
  • The polymerization technique used for the preparation of the polymer-drug conjugate of the present invention may propagate through free-radical polymerization or controlled/living free radical polymerization. Herein the term "controlled/living free radical polymerization" refers to atom transfer radical polymerization (ATRP), Reversible addition fragmentation chain transfer (RAFT) polymerization, iodine transfer polymerization (ITP), selenium centered radical mediated polymerization, telluride mediated polymerization (TERP), nitroxide mediated polymerization (NMP). In a preferred embodiment of the invention RAFT polymerization is used to prepare the polymer-drug conjugates of the invention.
  • A polymerization initiator as used herein refers to a chemical compound that reacts with a monomer to form an intermediate compound capable of linking successively with a large number of other monomers into a polymeric compound.
  • In an embodiment of the invention a polymerization initiator selected from the group disclosed in the above paragraphs of this document. In an embodiment of the invention methods I, II, III and/or IV used to prepare the polymer-conjugate of formula I comprises use of AIBN as initiator in the polymerization reactions.
  • In an embodiment of the invention the polymer-drug conjugate of the invention can further comprise targeting groups. Herein the term "targeting group" refers to tumor specific ligands that bind specifically to the cell, preferably the tumor cell that has a complimentary receptor.
  • The term "targeting group" means a molecule which serves to deliver the polymer-drug conjugate of the invention to a specific site for the desired activity, i.e. it provides localization of the compound. The localization is mediated by specific recognition of molecular determinants, molecular size of the targeting agent or conjugate, ionic interactions, hydrophobic interactions, and the like. Other mechanisms of targeting an agent to a particular tissue or region are known to those of skill in the art. Targeting ligands include, for example, molecules that bind to molecules on a targeted cell surface. Exemplary targeting ligands include antibodies, antibody fragments, small organic molecules, peptides, peptoids, proteins, polypeptides, oligosaccharides, transferrin, HS- glycoprotein, coagulation factors, serum proteins, beta-glycoprotein, G-CSF, GM-CSF, M-CSF, EPO, and the like. In exemplary embodiments of the present invention, the targeting system includes covalently attaching a targeting ligand such as RGDfK, EPPT1 peptide, bisphosphonic acid or folate to the carrier molecule or linker.
  • In certain embodiments, the present invention is characterized by polymer-drug conjugates with or without a targeting ligand. In some embodiments the targeting ligand can be RGDfK, EPPT1, bisphosphonic acid or folate.
  • Another embodiment of the present invention provides a method for delivering a therapeutic agent, comprising administering to a subject an effective amount of polymer-drug conjugate shown with formula I.
  • Another embodiment of the invention is the polymer-drug conjugate of the invention for use in treatment of a variety of disorders that require the delivery of anticancer or similar agents.
  • In a preferred embodiment, the invention is related to a polymer-drug conjugate shown with formula I for use as a medicament for treatment of cancer.
  • As used herein, "treat" or "treating" means to inhibit, reduce, modulate, ameliorate, or block at least one symptom that characterizes a pathologic condition, in a subject threatened by, or afflicted with, the condition. A non-limiting list of different types of cancers is as follows: carcinomas, carcinomas of solid tissues, squamous cell carcinomas, adenocarcinomas, sarcomas, gliomas, high grade gliomas, blastomas, neuroblastomas, plasmacytomas, histiocytomas, melanomas, adenomas, hypoxic tumours, myelomas, metastatic cancers, or cancers in general. Specific examples of of cancers that the disclosed compositions can be used to treat include B cell lymphoma, T cell lymphoma, mycosis fungoides, Hodgkin's Disease, bladder cancer, brain cancer, nervous system cancer, head and neck cancer, squamous cell carcinoma of head and neck, kidney cancer, lung cancers such as small cell lung cancer and non-small cell lung cancer, neuroblastoma/glioblastoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, liver cancer, melanoma, squamous cell carcinomas of the mouth, throat, larynx, colon cancer, cervical cancer, cervical carcinoma, breast cancer, and epithelial cancer, renal cancer, genitourinary cancer, pulmonary cancer, esophageal carcinoma, head and neck carcinoma, large bowel cancer, hematopoietic cancers; testicular cancer; colon and rectal cancers, prostatic cancer, or pancreatic cancer.
  • Polymer-drug conjugates of the invention may also be used for the treatment of precancer conditions such as cervical and anal dysplasias, other dysplasias, severe dysplasias, hyperplasias, atypical hyperplasias, and neoplasias.
  • The terms "cancer" and "cancerous" as used herein refers to malignant tumors or describe the physiological condition characterized by unregulated cell growth.
  • As discussed herein, polymer-drug conjugates of the present invention find use in the treatment and/or prophylaxis of cancer. For such use the polymer-drug conjugate of the present invention will generally be administered in the form of a pharmaceutical composition.
  • Thus, according to the invention there is provided a pharmaceutical composition comprising a polymer-drug conjugate according to formula I and at least one pharmaceutically acceptable diluent, excipient and/or carrier. The term "treatment" includes either therapeutic or prophylactic therapy.
  • The composition comprising the polymer-drug conjugate of the invention may be in any suitable form depending upon the desired method of administering it to a patient. The composition comprising polymer drug conjugates of the invention can be formulated to be administered orally, e.g. in the form of liquid dispersions or aqueous or oily suspensions or they can formulated for parenteral administration, for example for subcutaneous, intravenous, intramuscular, intrasternal, intraperitoneal, intradermal, transdermal or other infusion techniques. The composition comprising the polymer drug conjugates of the invention can also be formulated for administration by inhalation in form of an aerosol or solution for administration with and inhaler or nebulizer. The polymer-drug conjugates of the invention are preferably administered to a subject transdermally, subcutaneously, intranasally, intravenously, intramuscularly, intratumorally or via inhalation. The most suitable route for administration in any given case will depend on the particular therapeutic agent present in the polymer-drug conjugate of the present invention, the subject, and the nature and severity of the disease and the physical condition of the subject.
  • The polymer-drug conjugates of the invention may be administered in combination, e.g. simultaneously, sequentially or separately, with one or more other therapeutically active compounds, which may be an anti-cancer agent or it is an immunomodulatory, antiviral, antiinfective, antimicrobial, antiinfective or anesthetic agent or combinations thereof.
  • Said second therapeutic agent can be selected from the therapeutic agents listed above on the condition that it is different from the one present in the polymer-drug conjugate of the invention.
  • Comprising in the context of the present specification is intended to meaning including.
  • Where technically appropriate, embodiments of the invention may be combined.
  • Embodiments are described herein as comprising certain features/elements. The disclosure also extends to separate embodiments consisting or consisting essentially of said features/elements.
  • Technical references such as patents and applications are incorporated herein by reference.
  • Any embodiments specifically and explicitly recited herein may form the basis of a disclaimer either alone or in combination with one or more further embodiments.
  • The invention will now be described with reference to the following examples, which are merely illustrative and should not in any way be construed as limiting the scope of the present invention.
    • EXAMPLES Example 1: Preparation of Glycine-Phenylalanine-Leucine-Glycine (GFLG) cleavable linker having a methacrylate functional group
  • The GFLG-MA linker was prepared according to the literature method described in K.Ulbrich et al., Journal of Controlled Release, 64, 2000, 63-79.
    • Example 2: Preparation of Docetaxel-GFLG-Methacrylate(MA) monomer
  • Docetaxel (DTX) was coupled with the GFLG-MA linker according to the literature method described in Ghandehari et al., Mol. Pharm., 2011, 8(4), 1090-1099 to give DTX-GFLG-MA.
  • Docetaxel, (0.335g, 4.1 mmol), 4-(dimethylamino-) pyridine (DMAP, 0.049g, 4.0 mmol) and MA-GFLG-OH (0.188 g, 4.0 mmol) were dried under vacuum. The reaction mixture was dissolved under nitrogen in anhydrous N, N-dimethylformamide (DMF, 5 mL), cooled with an ice bath (salt/ice) at < 0°C and diisopropylcarbodiimide (DIPC, 76 µL, 4.89 mmol) was added dropwise.
  • The reaction mixture was subsequently stirred for an hour before the ice bath was removed and the mixture was allowed to warm up to room temperature, stirred overnight and progress was monitored by thin layer chromatography (TLC, eluent dichloromethane (DCM): methanol (MeOH) (95:5)) for the disappearance of the starting material and the formation of MA-GFLG-Docetaxel. DMF was removed under vacuum using rotary evaporator. The product was purified by silica gel chromatography.
    • Example 3: Preparation of Polymer-Drug conjugate comprising docetaxel and PEG in the side chains
  • Polyethylene glycol methyl ether methacrylate (PEGMEMA) (Mn: 300) and DTX-GFLG-MA was polymerized in presence of AIBN as initiator and DMF as solvent to yield PEGMEMA-DTX .
    Figure imgb0008
  • In the above figure (*) represents the AIBN fragments as the end groups of the polymer-drug conjugate.
  • By varying the ratio of the PEGMEMA it is possible to obtain PEGMEMA-DTX conjugates having different molecular weights.
  • In order to demonstrate that the invention is applicable over various molecular weights of PEGMEMA-DTX conjugates, the inventors prepared 50 kDa and 85 kDa PEGMEMA-DTX polymer-drug conjugates and subjected them to pharmacokinetic testing.
    • Example 4: Results of Pharmacokinetic Study
  • PEGMEMA-DTX conjugates having 50kDa and 85 kDa molecular weight were subjected to pharmacokinetic testing and its pharmacokinetic profile was compared with that of free DTX.
  • Pharmacokinetic parameters for total DTX were calculated using the plasma total DTX concentration values of polymer drug conjugates and free DTX. Half-life, volume of distribution (VDβ), clearance (CL), and total area under the curve (AUC total) were calculated.
  • For the sake of comparison with the known prior art, the applicants have prepared N-(2-hydroxypropyl)methacrylamide (HPMA)-GFLG-DTX polymers having molecular weight of 52 kDa and 85 kDa according to the known prior art methods disclosed in Ghandehari et al., Mol. Pharm., 2011, 8(4), 1090-1099. In order to provide similarity the HPMA-GFLG-DTX polymer was prepared without RGDfK targeting group.
  • The results of pharmacokinetic tests are shown in Table 1. Table 1: Pharmacokinetic parameters of PEGMEMA-GFLG-DTX conjugates, HPMA-GFLG-DTX conjugates and free DTX
    Half Life (p)(hour) VDp (mL) CL (mL/hr) AUC total (ug/mL.hr)
    Free DTX 3.12 ± 0,88 664.1 ± 258.1 140.4 ± 42.1 10 ± 3
    HPMA 52kDa-DTX 11.99 ± 0.37 102.5 ± 13.8 5.9 ± 0.7 241 ± 32
    HPMA 85kDa-DTX 16.24 ± 4.40 60.2 ± 11.1 2.6 ± 0.2 525 ± 57
    PEGMEMA 50kDa-DTX 14.62 ± 0.54 20.2 ± 1.9 1.0 ± 0.1 1357 ± 109
    PEGMEMA 85kDa-DTX 12.10 ± 0.35 10.0 ± 0.2 0.6 ± 0.0 2370 ± 106
  • When table 1 is taken into account, it is seen that both PEGMEMA-DTX conjugates have superior pharmacokinetic properties compared to the free therapeutic agent and HPMA-DTX conjugate. This result is indicative of the fact that the polymer-drug conjugate of the present invention provides a superior polymer-drug conjugate having longer half-life, lower clearance and larger AUC with respect to free DTX and DTX bound to HPMA polymer.
    • Example 5: Cytotoxicity Results of PEGMEMA-DTX conjugates and Free DTX for BxPC3 Cells
  • Human pancreas adenocarcinoma (BxPC3) cells were treated with conjugates and free DTX for 72 hours in DMEM medium. CCK-8 assay was performed to measure cell viability. PEGMEMA-DTX conjugates showed less cytotoxicity compared to free DTX conjugates which are desirable. The EC50 values of the polymer drug conjugates and free DTX are shown in table 2. Table 2: EC50 values of Free DTX and PEGMEMA-DTX conjugates
    EC50 Values [M]
    Free DTX < 1.0 x 10 -13
    PEGMEMA 50kDa-DTX 9.1 x 10 -11
    PEGMEMA 85kDa-DTX 3.0 x 10 -9
    • Example 6: Blood toxicity of PEGMEMA-DTX and Free DTX
  • Blood samples (200 µL) were collected just before and after 24 hours of the injection. Whole blood counter was used to measure the hemogram values of the samples. The relative change after 24 hours of the injection compared to before injection values were presented in Figure 1. White Blood Cell (WBC) Red Blood Cell (RBC) and Haemoglobin (HGB) and Haematocrit (HCT) values were evaluated. Low molecular weight conjugates had lower toxicity compared to high molecular weight ones on WBC. All conjugates showed less toxicity on RBC compared with free DTX. These results were also validated with HGB and HCT.
  • All in all, the results of the pharmacokinetic testing and cell and blood toxicity testing show that polymer-drug conjugates of the invention have better and unexpected properties with respect to known prior art and thus the present invention surpass the current state of the art.
    • Explanation of Drawings
  • Figure 1 is a graph showing percent hemogram values of PEGMEMA-DTX conjugates and free DTX.

Claims (13)

  1. A polymer-drug conjugate of formula I
    Figure imgb0009
     wherein
    o R1 and R2 are independently selected from H or -CH3; R3 is selected from -H or -CH3;
    o x is a natural number between 1-100;
    o y is a natural number between 1-100;
    o n is a natural number between 1-200 and
    o L is a cleavable linker and
    o D is at least one therapeutic agent;
    o Z is selected from -O or -NH;
    o A is an end group that is optionally a polymerization initiator or a fragment thereof
    o B is an end group that is optionally a polymerization initiator or a fragment thereof
  2. A polymer-drug conjugate according to claim 1 wherein the linker is selected from a group comprising a poly(ethylene glycol), an amino acid, poly(amino acid), polypeptide and short peptides.
  3. A polymer-drug conjugate according to claim 2 wherein the linker is a short peptide that is cathepsin B labile.
  4. A polymer-drug conjugate according to claim 3 wherein the short peptide is selected from a group comprising Gly-Phe-Leu-Gly (SEQ ID NO: 1), Val-Cit (SEQ ID NO:2), Phe-Lys (SEQ ID NO: 3), Val-Ala (SEQ ID NO: 4), Ala-Leu-Ala-Leu (SEQ ID NO: 5).
  5. A polymer-drug conjugate according to claim 1 wherein, the linker is a C1-C10 hydrocarbon or C1-C10 substituted or hetero substituted hydrocarbon, which comprises a functional group that dissociates under physiological conditions, preferably said functional group is selected from acetal, ester, imine, amide, disulfide, carbonate, hydrazine, carbamate.
  6. A polymer-drug conjugate according to any one of claims 1-5 wherein the therapeutic agent(s) is selected from a group comprising nucleoside analogs, antifolates, other metabolites, topoisomerase I inhibitors, anthracyclines, podophyllotoxins, taxanes, vinca alkaloids, alkylating agents, platinum compounds, antihormones, radiopharmaceutics, monoclonal antibodies, tyrosine kinase inhibitors, mammalian target of rapamycin (mTOR) inhibitors, retinoids, immunomodulatory agents, histonedeacetylase inhibitors and other agents.
  7. A polymer-drug conjugate according to claim 6 wherein the therapeutic agent(s) is selected from a group comprising docetaxel, pemetrexed, chloroquine, combretastatin, gemcitabine, doxorubicine, 5-FU, 5'-Deoxy 5-Fluorocytidine (5'-DFCR), lapatinib.
  8. A method for preparation of polymer drug conjugate of formula I according to claim 1 comprising polymerization of PEG (meth)acrylate monomer (formula II)
    Figure imgb0010
     and at least one type of (meth)acrylate-L-D monomer (formula IIIa)
    Figure imgb0011
     wherein R1 and R2 are independently selected from H or -CH3; R3 is selected from -H or - CH3; L is a cleavable linker; D is a therapeutic agent and n is a natural number between 1-200 to give formula I.
  9. A method for preparation of polymer-drug conjugate of formula I according to claim 1 comprising (i) polymerization of PEG (meth)acrylate monomer (formula II) according to claim 8 and (meth)acrylate-L monomer (Formula IIIb)
    Figure imgb0012
     wherein R1 and R2 are independently selected from H or -CH3; R3 is selected from -H or -CH3; L is a cleavable linker and n is a natural number between 1-200 to give a copolymer of formula IV
    Figure imgb0013
     wherein x is a natural number between 1-100 and y is a natural number between 1-100, Z is selected from O or -NH, A is an end group that is optionally a polymerization initiator or a fragment thereof, B is an end group that is optionally a polymerization initiator or a fragment thereof and then (ii) reacting formula IV with at least one therapeutic agent (D) to give formula I.
  10. A method for preparation of polymer-drug conjugate of formula I according to claim 1 comprising (i) polymerization of PEG (meth)acrylate monomer (Formula II) according to claim 8 and (meth)acrylate monomer (formula IIIc)
    Figure imgb0014
     wherein R1 and R2 are independently selected from H or -CH3; R3 is selected from -H or - CH3; R4 is selected from carbonyl activating groups such as perfluorophenoxy, maleimide, carbonate, thiazolidone-2-thione, N-oxybenzotriazole, imidazolyl, o/p-nitrophenoxy, pentachloro-phenoxy, N-hydroxysuccinimide, acetates, formates, 2,3,5-trichlorophenol, 8-hydroxyquinoline, and -OH, -OCH3, -OCH2CH3, Cl, F, Br, H, -SH, -NH2, -NHR5 or -OR5, R5 is C1-C10 saturated or unsaturated hydrocarbon and n is a natural number between 1-200 to give a copolymer of formula V
    Figure imgb0015
    o wherein x is a natural number between 1-100 and y is a natural number between 1-100, Z is selected from -O or -NH, A is an end group that is optionally a polymerization initiator or a fragment thereof, B is an end group that is optionally a polymerization initiator or a fragment thereof and then (ii) reacting formula V with at least one type of therapeutic agent attached to a linker (L-D) to give formula I.
  11. A method for preparation of polymer-drug conjugate of formula I according to claim 1 comprising (i) polymerization of PEG (meth)acrylate monomer (Formula II) according to claim 8 and (meth)acrylate monomer (formula IIIc)
    Figure imgb0016
     wherein R1 and R2 are independently selected from H or -CH3; R3 is selected from -H or - CH3 or -CH2CH3; R4 is selected from carbonyl activating groups such as perfluorophenoxy, maleimide, carbonate, thiazolidone-2-thione, N-oxybenzotriazole, imidazolyl, o/pnitrophenoxy, pentachloro-phenoxy, N-hydroxysuccinimide, acetates, formates, 2,3,5-trichlorophenol, 8-hydroxyquinoline and -OH, -OCH3, -OCH2CH3, Cl, F, Br, H, -SH, -NH2, -NHR5 or -OR5, R5 is C1-C10 saturated or unsaturated hydrocarbon and n is a natural number between 1-200 to give a copolymer of formula V
    • wherein x is a natural number between 1-100 and y is a natural number between 1-100, A is an end group that is optionally a polymerization initiator or a fragment thereof, B is an end group that is optionally a polymerization initiator or a fragment thereof and then (ii) reacting formula V with a linker (L) to give a copolymer of formula IV and (iii) reacting formula IV with at least one type of therapeutic agent (D) to give polymer conjugate of formula I.
  12. A pharmaceutical composition comprising a polymer-drug conjugate of formula I according to any one of claims 1-7.
  13. A polymer-drug conjugate of formula I according to any one of claims 1-7 for use as a medicament for treatment and/or prophylaxis of cancer.
EP17733906.6A 2016-06-30 2017-06-15 Cleavable polymer drug conjugates Active EP3478323B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
HRP20231642TT HRP20231642T1 (en) 2016-06-30 2017-06-15 Cleavable polymer drug conjugates
EP23178285.5A EP4260874A1 (en) 2016-06-30 2017-06-15 Cleavable polymer drug conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1611405.0A GB2551979A (en) 2016-06-30 2016-06-30 Cleavable polymer drug conjugates
PCT/IB2017/053567 WO2018002761A1 (en) 2016-06-30 2017-06-15 Cleavable polymer drug conjugates

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP23178285.5A Division EP4260874A1 (en) 2016-06-30 2017-06-15 Cleavable polymer drug conjugates
EP23178285.5A Division-Into EP4260874A1 (en) 2016-06-30 2017-06-15 Cleavable polymer drug conjugates

Publications (2)

Publication Number Publication Date
EP3478323A1 EP3478323A1 (en) 2019-05-08
EP3478323B1 true EP3478323B1 (en) 2023-09-27

Family

ID=56891421

Family Applications (2)

Application Number Title Priority Date Filing Date
EP23178285.5A Pending EP4260874A1 (en) 2016-06-30 2017-06-15 Cleavable polymer drug conjugates
EP17733906.6A Active EP3478323B1 (en) 2016-06-30 2017-06-15 Cleavable polymer drug conjugates

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP23178285.5A Pending EP4260874A1 (en) 2016-06-30 2017-06-15 Cleavable polymer drug conjugates

Country Status (18)

Country Link
US (1) US20190321479A1 (en)
EP (2) EP4260874A1 (en)
JP (1) JP6937329B2 (en)
KR (2) KR102539137B1 (en)
CN (1) CN109475637A (en)
AU (1) AU2017286869B2 (en)
BR (1) BR112019000029A2 (en)
CA (1) CA3029318A1 (en)
DK (1) DK3478323T3 (en)
EA (1) EA038984B1 (en)
FI (1) FI3478323T3 (en)
GB (1) GB2551979A (en)
HR (1) HRP20231642T1 (en)
IL (2) IL263965B2 (en)
MX (1) MX2019000277A (en)
PL (1) PL3478323T3 (en)
PT (1) PT3478323T (en)
WO (1) WO2018002761A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
GB2556055B (en) 2016-11-16 2022-03-23 Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret Ltd Sti Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
EP3710061A1 (en) * 2017-11-17 2020-09-23 Centre National de la Recherche Scientifique Polymer prodrugs and subcutaneous and/or intramuscular administration thereof
CN108752507A (en) * 2018-05-12 2018-11-06 辽宁大学 A kind of enzyme sensitivity and isotope of redox-sensitive double-response type copolymer and its preparation method and application
CA3152111A1 (en) * 2019-09-26 2021-04-01 David James Owen Therapeutic dendrimer
CN112608364B (en) * 2020-12-09 2023-08-29 四川瀛瑞医药科技有限公司 Pectin-doxorubicin conjugate and preparation method of intermediate thereof
CN115010913B (en) * 2022-06-17 2023-05-26 广东工业大学 PH/reduction dual-response polymer micelle and preparation method and application thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636889A1 (en) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastic transferrin and albumin conjugates of cytostatic compounds from the group of the anthracyclines, alkylating agents, antimetabolites and cisplatin analogues and medicaments containing them
EP0998303B1 (en) 1997-06-12 2006-02-15 Innovata PLC Polymer-drug conjugate for the treatment of cancer
US6524583B1 (en) 1999-04-28 2003-02-25 Board Of Regents, The University Of Texas System Antibody methods for selectively inhibiting VEGF
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
CZ2005558A3 (en) * 2005-09-05 2007-04-04 Zentiva, A. S. Process for preparing doxorubicin polymeric conjugates with pH-controlled release of medicament
US8017141B2 (en) * 2006-12-15 2011-09-13 Advanced Cardiovascular Systems, Inc. Coatings of acrylamide-based copolymers
CA2739757C (en) * 2008-10-07 2016-07-05 Rexahn Pharmaceuticals, Inc. Hpma - docetaxel or gemcitabine conjugates and uses therefore
CZ303072B6 (en) * 2009-02-13 2012-03-21 Zentiva, K.S. Paclitaxel and docetaxel polymeric conjugates with pH controlled release of cancerostatic
CN104587484A (en) * 2009-10-13 2015-05-06 瑞沙恩医药公司 Polymeric systems for the delivery of anticancer drugs
JP5681285B2 (en) * 2010-07-28 2015-03-04 コーニング インコーポレイテッド Prepolymer preparation for cell culture coating
WO2014152451A2 (en) * 2013-03-14 2014-09-25 University Of Rochester Compositions and methods for controlled localized delivery of bone forming therapeutic agents
CN105168230B (en) * 2015-09-02 2019-01-22 上海市普陀区中心医院 A kind of cancer target prodrug and its nanometer formulation and preparation method with endosome escape function

Also Published As

Publication number Publication date
EA038984B1 (en) 2021-11-18
WO2018002761A1 (en) 2018-01-04
AU2017286869A8 (en) 2019-02-14
CN109475637A (en) 2019-03-15
EP4260874A1 (en) 2023-10-18
IL263965A (en) 2019-01-31
GB2551979A (en) 2018-01-10
KR20230035709A (en) 2023-03-14
FI3478323T3 (en) 2023-12-20
EP3478323A1 (en) 2019-05-08
JP2019527209A (en) 2019-09-26
IL263965B1 (en) 2023-06-01
AU2017286869A1 (en) 2019-02-07
HRP20231642T1 (en) 2024-03-15
AU2017286869B2 (en) 2022-05-05
BR112019000029A2 (en) 2019-04-24
MX2019000277A (en) 2019-05-27
IL302564A (en) 2023-07-01
DK3478323T3 (en) 2024-01-02
US20190321479A1 (en) 2019-10-24
CA3029318A1 (en) 2018-01-04
KR102539137B1 (en) 2023-06-01
JP6937329B2 (en) 2021-09-22
GB201611405D0 (en) 2016-08-17
EA201990142A1 (en) 2019-06-28
IL263965B2 (en) 2023-10-01
KR20190022718A (en) 2019-03-06
PT3478323T (en) 2024-01-02
PL3478323T3 (en) 2024-03-04

Similar Documents

Publication Publication Date Title
EP3478323B1 (en) Cleavable polymer drug conjugates
JP6013424B2 (en) HPMA-docetaxel conjugate and use thereof
AU2017362067B2 (en) Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
US8846110B2 (en) Polymeric systems for the delivery of anticancer drugs
EA044119B1 (en) SELF-ASSEMBLED DIBLOCK COPOLYMERS CONSISTED OF PEGMEMA AND DRUG-CARRIING POLYMER SEGMENTS

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20231642T

Country of ref document: HR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190115

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200622

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230201

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAL Information related to payment of fee for publishing/printing deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230605

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20230705

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017074644

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3478323

Country of ref document: PT

Date of ref document: 20240102

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20231221

Ref country code: DK

Ref legal event code: T3

Effective date: 20231215

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20230927

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20230402536

Country of ref document: GR

Effective date: 20240209

Ref country code: SK

Ref legal event code: T3

Ref document number: E 43147

Country of ref document: SK

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20231642

Country of ref document: HR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240127

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1614749

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230927